Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis

Next Previous
X
Search
Trial Profile

A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abatacept (Primary) ; Methotrexate
  • Indications Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms ASTRAEA; PsA-II
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 17 Jun 2021 Status changed from active, no longer recruiting to completed.
    • 11 Feb 2021 This trial has been completed in Poland (Global End Date: 30 Jun 2020), according to European Clinical Trials Database record.
    • 27 Aug 2020 This trial has been completed in Germany (30 June 2020).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top